Rocket Pharmaceuticals (RCKT) — Q4/FY 2025 results, runway reset, and the March 28 PDUFA clock

1) What’s new in this update (and what is not)

The cleanest way to read the latest Rocket update is to separate timeline reaffirmations from execution questions. The headline reaffirmation is straightforward: Rocket again pointed to the March 28, 2026 PDUFA target action date for KRESLADI (RP-L201) in severe LAD-I, and it explicitly reminded the market that approval would make the company eligible for a Rare Pediatric Disease Priority Review Voucher. That combination (hard date + potential PRV) is exactly the kind of setup that creates a run-up window, even in a tape that is skeptical.

What did not change: Rocket did not re-write the fundamental nature of the risk. This is still a name where traders care about manufacturing reliability, operational discipline, and how much of the company’s future gets “dragged” into one late-March binary. The filing does not magically dissolve those uncertainties — it simply anchors the market’s calendar and refreshes the cash math.

2) The numbers that matter right now: cash, runway, and the “survival math”

For a catalyst-driven gene therapy stock trading at a depressed valuation, the most practical question is often not the long-term TAM story, but the short-term survival math: how long can the company operate without a forced financing, and how credible is the runway guidance? Rocket disclosed $188.9M in cash, cash equivalents and investments as of December 31, 2025, and guided that those resources should fund operations into the second quarter of 2027, explicitly excluding any potential future PRV proceeds. In the same document, Rocket also gave a clean reference point for dilution watchers: 108,319,783 shares outstanding at year-end.

The cost structure, at least as expressed through full-year operating lines, also showed the footprint of the company’s organizational realignment: R&D expense was $142.0M for FY 2025 versus $171.2M in FY 2024, and G&A was $86.5M versus $102.0M the year before. Net loss for FY 2025 was $223.1M (or $2.01 per share), improved versus FY 2024’s $258.7M (or $2.73 per share).

None of those numbers are, by themselves, a “bull case.” They are simply the mechanical inputs that decide how much time Rocket has to execute into late March and then into the post-decision period. A PRV, if it exists, can change the cash narrative. But the company was careful: the runway statement is made without assuming PRV proceeds. That is the conservative way to present it, and for readers, it is the correct baseline.

3) Pipeline headline: KRESLADI (LAD-I) is the calendar; everything else is optionality (for now)

Rocket can talk about multiple platforms and multiple programs, but the stock’s near-term “magnet” is still KRESLADI in severe LAD-I. The company reiterated that the FDA accepted the resubmission of the BLA and that, in October 2025, the program received a PDUFA target action date of March 28, 2026. If the market is trading RCKT like a compressed option, it is because late March is a hard date that forces positioning and creates a narrative checkpoint.

The second piece of this headline is the PRV reminder: the company stated that Rocket is eligible for a Rare Pediatric Disease PRV with the approval of KRESLADI. Traders will treat this like a “bonus lever” because PRVs can be monetized, but the right way to present this to readers is simple and honest: it is conditional, it is not guaranteed, and its value depends on the market environment when/if it exists.

4) Cardiovascular gene therapy update: what Rocket said about Danon, PKP2-ACM, and BAG3

The filing made a point of placing Rocket’s 2026 story inside cardiovascular gene therapy, not only LAD-I. The most concrete Danon detail is that the pivotal Phase 2 trial of RP-A501 is expected to dose additional patients in the first half of 2026. Rocket also repeated the prior milestone that, in August 2025, the FDA lifted the clinical hold in under three months, and that the next dosing will occur under a recalibrated dose (3.8 × 10¹³ GC/kg), with at least a four-week interval between patients and a modified immunomodulatory regimen, after which Rocket will align with FDA on completion of the pivotal Phase 2 study.

For BAG3-related dilated cardiomyopathy, Rocket stated that dosing of the first patient in the Phase 1 study of RP-A701 is anticipated in mid-2026. On PKP2-ACM, the company emphasized advancing alignment with FDA on pivotal study design. These are important because they keep the “platform” narrative alive, but readers should understand the hierarchy: unless late March goes well, many market participants will refuse to pay today for longer-dated cardio optionality.

5) How to think about the tape into March 28 (without pretending to predict it)

The most honest way to write the “market view” here is to describe how stocks like this behave into hard dates, rather than to perform confidence theater. Into late March, RCKT will likely be driven by some mix of: (1) calendar compression as the PDUFA date approaches, (2) risk appetite in the broader biotech complex, (3) headline sensitivity around manufacturing and regulatory posture in gene therapy, and (4) positioning dynamics (fast money vs. longer-term holders).

From a RunUP Biotech lens, this is exactly the kind of setup where readers benefit from clarity: the “run-up” is not a guarantee and not a moral stance. It is a behavioral pattern that sometimes appears when a hard catalyst date attracts attention and forces positioning. A clean article should emphasize the conditions that support a run-up (clear date, liquid enough tape, visible narrative) and the conditions that kill it (risk-off regime, negative regulatory chatter, a secondary safety headline, or sudden financing fear).